Genelux Corporation (NASDAQ: GNLX) Stock Information | RedChip

Genelux Corporation (NASDAQ: GNLX) Listen to this Section


$2.03
-0.1000 ( -4.69% ) 60.6K

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Market Data


Open


$2.03

Previous close


$2.13

Volume


60.6K

Market cap


$69.39M

Day range


$2.02 - $2.16

52 week range


$1.60 - $30.44

Insider Ownership Transactions

Total Amount Purchased: -176,060.00 | $ -357,401.80

Date Type Amount Purchased Purchaser
2024-08-05 Sale -39541.00 Smither John W
2024-08-05 Sale -39541.00 Mirabelli Mary
2024-08-05 Sale -39541.00 Tyree James L
2024-08-05 Sale -39541.00 Thomas John
2024-07-08 Sale -3661.00 Yu Yong
2024-07-08 Sale -1143.00 Jewett Caroline
2024-07-08 Sale -2936.00 Ryder Sean
2024-07-08 Sale -616.00 Smalling Ralph
2024-07-08 Sale -8320.00 Zindrick Thomas
2024-07-08 Sale -1220.00 Zak Lourie S.

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 59 Aug 14, 2024
8-k 8K-related 13 Aug 06, 2024
4 Insider transactions 1 Aug 05, 2024
4 Insider transactions 1 Aug 05, 2024
4 Insider transactions 1 Aug 05, 2024
4 Insider transactions 1 Aug 05, 2024
8-k 8K-related 42 Aug 01, 2024
4 Insider transactions 1 Jul 08, 2024
4 Insider transactions 1 Jul 08, 2024
4 Insider transactions 1 Jul 08, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.